Should You Buy Pacific Biosciences of California (PACB)?
To the average investor, there are tons of metrics shareholders can use to analyze Mr. Market. A duo of the best are hedge fund and insider trading interest.
Chelsea Therapeutics International Ltd. (CHTP)
This company is not actively trading or the ticker does belong to another company in our database now.
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Whitebox Advisors Andy Redleaf | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.32 | 4,900 | $6,467.51 | 450,178 | 2012-06-05 | Filing | |
| $1.32 | 100 | $132.00 | 445,278 | 2012-06-05 | Filing | |
| $1.31 | 8,000 | $10,480.00 | 11,000 | 2012-06-04 | Filing | |
| $4.50 | 4,000 | $18,007.60 | 8,305,049 | 2012-01-27 | Filing | |
| $4.46 | 13,900 | $61,994.00 | 8,301,049 | 2012-01-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.92 | 439,308 | $402,054.68 | 6,432,673 | 2012-12-17 | Filing | |
| $0.95 | 249,249 | $236,811.47 | 6,871,981 | 2012-12-14 | Filing | |
| $0.92 | 439,308 | $402,054.68 | 6,432,673 | 2012-12-17 | Filing | |
| $0.95 | 249,249 | $236,811.47 | 6,871,981 | 2012-12-14 | Filing | |
| $1.05 | 399,414 | $419,384.70 | 7,121,230 | 2012-12-12 | Filing |
News See All
Is Pacific Biosciences of California (PACB) Going to Burn These Hedge Funds?
Pacific Biosciences of California (NASDAQ:PACB) was in 7 hedge funds' portfolio at the end of the first quarter of 2013.
Geron Corporation (GERN): Are Hedge Funds Right About This Stock?
To most investors, hedge funds are assumed to be worthless, old investment tools of the past.
Avoid This Biotech Stock: Chelsea Therapeutics International Ltd. (CHTP)
Editor's note: This article is a stock pitch made by a member on CAPS, The Motley Fool's free investing community.
This Week in Biotech: VIVUS, Inc. (VVUS), Roche Holdings Ltd-Spons Adr (RHHBY)
With the SPDR S&P Biotech Index up 25% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.